The improved efficacy of a fixed-dose combination of fluticasone furoate and levocabastine relative to the individual components in the treatment of allergic rhinitis

Clinical and Experimental Allergy

Volumn 45, Issue 8, 2015, Pages 1346-1355

  Murdoch, R D ^a   Bareille, P ^a   Ignar, D ^b   Miller, S R ^a   Gupta, A ^c   Boardley, R ^a   Zieglmayer, P ^d   Zieglmayer, R ^d   Lemel, P ^d   Horak, F ^d  

^a GLAXOSMITHKLINE   (United Kingdom)

^b GLAXOSMITHKLINE   (United States)

^c GlaxoSmithKline Pharmaceuticals Ltd   (India)

^d Vienna Challenge Chamber   (Austria)

Author keywords

Allergy; Antihistamine; Efficacy; Steroids

Indexed keywords

FLUTICASONE FUROATE; FLUTICASONE FUROATE PLUS LEVOCABASTINE; LEVOCABASTINE; PLACEBO; UNCLASSIFIED DRUG; ANDROSTANE DERIVATIVE; PIPERIDINE DERIVATIVE;

ADULT; ALLERGIC RHINITIS; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SYMPTOM ASSESSMENT; TOTAL NASAL SYMPTOM SCORE; TOTAL OCULAR SYMPTOM SCORE; ADOLESCENT; AGED; COMBINATION DRUG THERAPY; MIDDLE AGED; PROCEDURES; RHINITIS, ALLERGIC;

ADOLESCENT; ADULT; AGED; ANDROSTADIENES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERIDINES; RHINITIS, ALLERGIC;

EID: 84937460021     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/cea.12556     Document Type: Article

References (40)

1. Scadding GK, Durham SR, Mirakian R et al. BSACI guidelines for the management of allergic and non-allergic rhinitis. Clin Exp Allergy 2008; 38:19-42.
2. Bousquet J, Khaltaev N, Cruz AA et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008; 63:8-160.
3. Demoly P, Calderon MA, Casale T et al. Assessment of disease control in allergic rhinitis. Clin Transl Allergy 2013; 3:7.
4. Greiner AN, Hellings PW, Rotiroti G, Scadding GK. Allergic rhinitis. Lancet 2011; 378:2112-22.
5. Hansen I, Klimek L, Mösges R, Hörmann K. Mediators of inflammation in the early and the late phase of allergic rhinitis. Curr Opin Allergy Clin Immunol 2004; 4:159-63.
6. Shedden A. Impact of nasal congestion on quality of life and work productivity in allergic rhinitis. Treat Respir Med 2005; 4:439-46.
7. Juniper EF, Guyatt GH, Dolovich J. Assessment of quality of life in adolescents with allergic rhinoconjunctivitis: developing and testing of a questionnaire for clinical trials. J Allergy Clin Immunol 1994; 93:413-23.
8. Laforest L, Bousquet J, Pietri G et al. Quality of life during pollen season in patients with seasonal allergic rhinitis with or without asthma. Int Arch Allergy Immunol 2005; 136:281-6.
9. Kauppi P, Salo P, Hakola R et al. Allergic rhinitis alone or with asthma is associated with an increased risk of sickness absences. Respir Med 2010; 104:1654.
10. Blaiss MS on behalf of The Allergic Rhinitis in Schoolchildren Consensus Group. Allergic rhinitis and impairment issues in schoolchildren: a consensus report. Curr Med Res Opin 2004;20:1937-1952.
11. Blaiss MS. Allergic rhinitis: direct and indirect costs. Allergy Asthma Proc 2010; 31:375-80.
12. Price D, Bond C, Bouchard J et al. International Primary Care Respiratory Group (IPCRG) guidelines: management of allergic rhinitis. Prim Care Respir J 2006; 15:58-70.
13. Kaliner MA. Azelastine and olopatadine in the treatment of allergic rhinitis. Ann Allergy Asthma Immunol 2009; 103:373-80.
14. Baroody FM, Foster K, Markarian A, DeTineo M, Naclerio RM. Nasal ocular reflexes and eye symptoms in patients with allergic rhinitis. Ann Allergy Asthma Immunol 2008; 100:194-9.
15. Baroody FM, Shenaq D, DeTineo M, Wang JH, Naclerio RM. Fluticasone furoate nasal spray reduces the nasal-ocular reflex: a mechanism for the efficacy of topical steroids in controlling allergic eye symptoms. J Allergy Clin Immunol 2009; 123:1342-8.
16. Canonica GW, Bousquet J, Mullol J, Scadding GK, Virchow JC. A survey of the burden of allergic rhinitis in Europe. Allergy 2007; 62(Suppl 85):17-25.
17. Schatz M. A survey of the burden of allergic rhinitis in the USA. Allergy 2007; 62(Suppl 85):9-16.
18. Navarro A, Valero A, Rosales MF, Mullol J. Clinical use of oral antihistamines and intranasal corticosteroids in patients with allergic rhinitis. J Investig Allergol Clin Immunol 2011; 21:363-9.
19. Ratner PH, Hampel F, Van Bavel J et al. Combination therapy with azelastine hydrochloride nasal spray and fluticasone propionate nasal spray in the treatment of patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2008; 100:74-81.
20. Nathan RA, Berger W, Yang W et al. Effect of once-daily fluticasone furoate nasal spray on nasal symptoms in adults and adolescents with perennial allergic rhinitis. Ann Allergy Asthma Immunol 2008 May; 100:497-505.
21. Fokkens WJ, Jogi R, Reinartz S et al. Once daily fluticasone furoate nasal spray is effective in seasonal allergic rhinitis caused by grass pollen. Allergy 2007; 62:1078-84.
22. McCormack PL, Scott LJ. Fluticasone furoate: intranasal use in allergic rhinitis. Drugs 2007; 67:1905-15.
23. Janssens MM-L, Vanden Bussche G. Levocabastine: an effective topical treatment of allergic rhinoconjunctivitis. Clin Exp Allergy 1991; 21(Suppl 2):29-36.
24. Corren J, Rachelefsky G, Spector S et al. Onset and duration of action of levocabastine nasal spray in atopic patients under nasal challenge conditions. J Allergy Clin Immunol 1999; 103:574-80.
25. Horak F, Stubner UP, Zieglmayer R, Harris AG. Effect of desloratadine vs. placebo on nasal airflow and subjective measures of nasal obstruction in subjects with grass pollen-induced allergic rhinitis in an allergen-exposure unit. J Allergy Clin Immunol 2002; 109:956-61.
26. Horak F, Stubner P, Zieglmayer R, Harris AG. Comparison of the effects of desloratadine 5-mg daily and placebo on nasal airflow and seasonal allergic rhinitis symptoms induced by grass pollen exposure. Allergy 2003; 58:481-5.
27. Day JH, Horak F, Briscoe MP et al. The role of allergen challenge chambers in the evaluation of anti-allergic medication: an international consensus paper. Clin Exp Allergy Reviews 2006; 6:31-59.
28. Dechant KL, Goa KL. Levocabastine. A review of its pharmacological properties and therapeutic potential as a topical antihistamine in allergic rhinitis and conjunctivitis. Drugs 1991; 41:202-24.
29. Blaiss MS. Ocular signs and symptoms elicited by a naturalistic allergen challenge in an Environmental Exposure Chamber model vs. a direct instillation model. World Allergy Organ J 2012; 5(Suppl 2):S35.
30. Scadding G, Keith P. Fluticasone furoate nasal spray consistently and significantly improves both the nasal and ocular symptoms of seasonal allergic rhinitis: a review of the clinical data. Expert Opin Pharmacother 2008; 9:2707-15.
31. Bielory L. Ocular symptom reduction in patients with seasonal allergic rhinitis treated with the intranasal corticosteroid mometasone furoate. Ann Allergy Asthma Immunol 2008; 100:272-9.
32. Naclerio RM. Intranasal corticosteroids reduce ocular symptoms associated with allergic rhinitis. Otolaryngol Head Neck Surg 2008; 138:129-39.
33. Schata M, Jorde W, Richarz-Barthauer U. Levocabastine nasal spray better than sodium cromoglycate and placebo in the topical treatment of rhinitis. J Allergy Clin Immunol 1991; 87:873-8.
34. Price D, Shah S, Bhatia S et al. A new therapy (MP29-02) is effective for the long-term treatment of chronic rhinitis. J Investig Allergol Clin Immunol 2013; 23:495-503.
35. Weller JM, Meltzer EO, Benson PM, Weller K, Widlitz MD, Freitag J. A dose-ranging study of the efficacy and safety of azelastine nasal spray in the treatment of seasonal allergic rhinitis with an acute model. J Allergy Clin Immunol 1994; 94:972-80.
36. Dymista Package Insert. (Last accessed 31 October 2013). http://medlibrary.org/lib/rx/meds/dymista/
37. South Africa Livostin package insert. (Last revised May 2009) http://www.meppo.com/pdf/drugs/1028-LIVOSTIN-NASAL-SPRAY-1329751247.pdf
38. Mosges R, Spaethl J, Klimek L. Efficacy and tolerability of levocabastine and azelastine nasal sprays for the treatment of allergic rhinitis. Mediators Inflamm 1995; 4:S11-5.
39. Meltzer EO, Andrews C, Journeay GE et al. Comparison of patient preference for sensory attributes of fluticasone furoate or fluticasone propionate in adults with seasonal allergic rhinitis: a randomized, placebo-controlled, double-blind study. Ann Allergy Asthma Immunol 2010; 104:331-8.
40. Zieglmayer P, Zieglmayer R, Bareille P, Rousell V, Salmon E, Horak F. Fluticasone furoate vs. placebo in symptoms of grass-pollen allergic rhinitis induced by exposure in the Vienna Challenge Chamber. Curr Med Res Opin 2008; 24:1833-40.